ACFAS

Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

Retrieved on: 
Friday, February 2, 2024
HVA, Standard of care, Surgeon, IMA, American College, DPM, Trial of the century, Patient, Pain, TSP, Social, ACFAS, Bunion, Weight-bearing, Conference, Nursing

PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions were presented in a podium presentation at the 2024 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference .

Key Points: 
  • PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions were presented in a podium presentation at the 2024 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference .
  • “We believe these three-year clinical study results set a high standard for a commercial bunion technology and one that further differentiates Lapiplasty® in the marketplace with our surgeons and their patients.
  • The Company has submitted its primary endpoint ALIGN3D™ manuscript to a top-tier, peer-reviewed foot and ankle journal at the end of 2023 and expects publication in 2024.
  • More information on Treace’s products can be found at www.lapiplasty.com .

Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference

Retrieved on: 
Thursday, February 1, 2024
American College, PSI, ACFAS, Conference, Medical device

“Our continued strong presence at ACFAS underscores Treace's longstanding commitment to investing in the field of foot and ankle surgery,” said John T. Treace, CEO, Founder and Board Member of Treace.

Key Points: 
  • “Our continued strong presence at ACFAS underscores Treace's longstanding commitment to investing in the field of foot and ankle surgery,” said John T. Treace, CEO, Founder and Board Member of Treace.
  • “During this year’s ACFAS conference, we are excited to highlight several new innovations from our robust pipeline of ten focused product launches slated from the second half of 2023 through 2024.
  • The Micro-Lapiplasty™ System is now in full commercial release and will be featured in hands-on training workshops at the conference.
  • Recently introduced Hammertoe PEEK Fixation System and the LapiTome™ and RazorTome™ single-use osteotomes will also be featured at the conference.

Paragon 28 Launches PRECISION® MIS Bunion System Offering Surgeons a Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Retrieved on: 
Thursday, February 1, 2024
Health, Surgery, Other Health, Medical Devices, Paragon, Multimedia, Surgeon, American College, MIS, Patient, Rotation, ACFAS, Bunion, Annual general meeting, FNA, Osteotomy, Dentistry

Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique.
  • The PRECISION® MIS Bunion System includes cannulated chamfer screws for fixation that allow alignment of the metatarsal head near the cortex of the first metatarsal.
  • Surgeon designer David Gordon, MD, commented, “The PRECISION® MIS Bunion System by Paragon 28 really changes the landscape of minimally invasive hallux valgus correction, using a distal osteotomy.
  • With this comprehensive portfolio, Paragon 28® provides its customers with a single source to address their bunion needs.

restor3d to Debut New Foot & Ankle Offerings at ACFAS Annual Meeting

Retrieved on: 
Wednesday, January 31, 2024
Electronic Design Automation, Medical Devices, Technology, Artificial Intelligence, Health Technology, Science, Surgery, Engineering, Biotechnology, Manufacturing, Other Science, Health, Multimedia, Surgeon, American College, DPM, AI, Automation, Foot, Ankle, Cobalt, ACFAS, Conference, Medical imaging

Attendees at this year’s American College of Foot & Ankle Surgeons (ACFAS) Annual Conference in Tampa, Florida will be the first to see restor3d’s newest Foot & Ankle offerings.

Key Points: 
  • Attendees at this year’s American College of Foot & Ankle Surgeons (ACFAS) Annual Conference in Tampa, Florida will be the first to see restor3d’s newest Foot & Ankle offerings.
  • View the full release here: https://www.businesswire.com/news/home/20240131920647/en/
    restor3d announces the launch of new Foot & Ankle product offerings: Kinos Axiom® X-Stem Tall Total Ankle System and the Patient-Specific Total Talus.
  • Launching the Total Talus Replacement is a critical step towards distinctive patient-specific solutions for treating complex foot and ankle pathologies.
  • Visit restor3d Booth #931 in the exhibit hall or join Dr. Jason Miller, DPM Friday evening to Reimagine Personalization, February 2nd from 7:00 - 9:00 p.m.

Stryker Expands Prophecy® Surgical Planning System to Include the New Footprint™, Offering Surgeons a Comprehensive View of the Foot and Ankle

Retrieved on: 
Wednesday, January 31, 2024
Health, Medical Devices, Surgery, Other Health, General Health, Pharmaceutical, Biotechnology, Surgeon, American College, DPM, Infinity, Patient, Arthroplasty, Footprint, Pathology, Estate (law), SYK, Ankle, ACFAS, Annual general meeting, Pharmaceutical industry

Stryker (NYSE: SYK), a global leader in medical technologies, today announced the launch of Prophecy Footprint, an expansion of the Prophecy Surgical Planning system, offering comprehensive surgical planning across the entire foot.

Key Points: 
  • Stryker (NYSE: SYK), a global leader in medical technologies, today announced the launch of Prophecy Footprint, an expansion of the Prophecy Surgical Planning system, offering comprehensive surgical planning across the entire foot.
  • The system will be demonstrated at the American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting , Tampa Bay, Fla., Feb. 1-4 (booth #919).
  • The launch of Prophecy Footprint also coincides with the tenth anniversary of Stryker’s Infinity Total Ankle System, a low-profile implant indicated for total ankle replacement in patients with end-stage ankle arthritis.
  • Prophecy Footprint elevates surgical planning by providing comprehensive procedural considerations that address concomitant pathology at the time of total ankle arthroplasty.

Medline to launch Lisfranc System at ACFAS 2024 Annual Scientific Conference

Retrieved on: 
Tuesday, January 30, 2024
Surgeon, American College, Titanium, Anatomy, MEDLINE, Dislocation, Marketing, Fracture, Accident, Patient, Ligament, ACFAS, UNITE, Conference, Dentistry

NORTHFIELD, Ill., Jan. 30, 2024 /PRNewswire/ -- Attendees at this year's American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference in Tampa, Florida will be the first to see Medline UNITE's new Lisfranc Plating & Screw System. This new product adds to Medline UNITE's expansive portfolio of midfoot trauma and reconstruction implants.

Key Points: 
  • NORTHFIELD, Ill., Jan. 30, 2024 /PRNewswire/ -- Attendees at this year's American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference in Tampa, Florida will be the first to see Medline UNITE's new Lisfranc Plating & Screw System .
  • Lisfranc injuries can occur in a variety of ways from sports to motor vehicle accidents, and can result in sprains, fractures and dislocations.
  • The Medline UNITE Lisfranc Plating & Screw System offers 18 dual-ray Lisfranc plates that feature bendable and removable tabs to accommodate variations in patient anatomy.
  • "The biggest innovation in this new system is the Lisfranc targeting guide reduction clamp," said Dr. Jonathon D. Backus, MD of Vail, Colorado.

Enovis Showcases New Foot & Ankle Offerings at the ACFAS Annual Meeting

Retrieved on: 
Monday, January 29, 2024
ACFAS, Foot, MIS, Deformity, Acquisition, Surgeon, DJO, American College, ENOV

WILMINGTON, DE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Today, Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced it will showcase the latest technologies from its Global Foot and Ankle business at the American College of Foot & Ankle (ACFAS) annual meeting in Tampa, Fla., from February 1-4, 2024.

Key Points: 
  • WILMINGTON, DE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Today, Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced it will showcase the latest technologies from its Global Foot and Ankle business at the American College of Foot & Ankle (ACFAS) annual meeting in Tampa, Fla., from February 1-4, 2024.
  • “With a commitment to advancing technology and improving user experience, we are proud to share our newest technologies at this year’s meeting,” stated Gary Justak, President and General Manager of Enovis™ Foot and Ankle.
  • Additionally, Enovis will be introducing the all new EF1 External Fixation product line, complimenting the flagship DynaNail® and DynaClip™ offerings in the hindfoot segment.
  • Enovis will also highlight products from its foot and ankle continuum of care, including the following products from its subsidiary DJO, LLC:

OSSIO’s Groundbreaking Option for Fixing Bone Fractures In Children Receives FDA Clearance

Retrieved on: 
Wednesday, December 6, 2023
Medical Devices, FDA, Health, Technology, Surgery, Hardware, Foot, Arthrodesis, Food, Elective surgery, Nail, Anatomy, Regeneration, Risk, Surgeon, IPOS, Immobilization, Ankle, Patient, Multimedia, GameChanger, Fracture, Ankle fracture, American College, DPM, Child, Anxiety, Wrist, Hand, Trial of the century, Trauma, Knee, Fibula, Sports medicine, Growth, Parent, ACFAS, Medical device, Dentistry, Ceramic

View the full release here: https://www.businesswire.com/news/home/20231206064383/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231206064383/en/
    The FDA has cleared the company’s OSSIOfiber® bio-integrative fixation technology for use in orthopedic surgery for children and adolescents needing bone fractures fixed, osteotomies, or fusions.
  • As a result, OSSIOfiber Compression Screws and Trimmable Fixation Nails may now be used in children from age two to 21 years in standard clinical practice.
  • Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber Intelligent Bone Regeneration Technology is a first-of-its-kind implant material stronger than cortical bone.
  • It can address many surgical applications through the manufacturing of endless implant designs, including nails, screws, staples, anchors and plates.

Roberto Morandotti wins Acfas Urgel-Archambault award

Retrieved on: 
Friday, November 17, 2023
Interdisciplinarity, Research, Nature, Creativity, Physics, INRS, Telecommunications, Prix, Ethics, Student, Faculty, Internet, Laser, Artificial intelligence, Intelligence, Laboratory, Pierre-Urgel Archambault, Terahertz, Knowledge, Education minister, Patent, Pharmaceutical industry, Nursing, Film industry, Management, Science, ACFAS

Professor at INRS's Centre Énergie Matériaux Télécommunications since 2003, he is this year's recipient of the Acfas Urgel-Archambault award for outstanding scientists.

Key Points: 
  • Professor at INRS's Centre Énergie Matériaux Télécommunications since 2003, he is this year's recipient of the Acfas Urgel-Archambault award for outstanding scientists.
  • Thanks to the excellence of our teams, we have nothing to envy other laboratories on the planet," says professor Morandotti.
  • "Roberto Morandotti is a world-renowned professor who has revolutionized the field of nonlinear and quantum optics, as well as its technological applications.
  • Finally, it is a great honor for Roberto Morandotti to promote science and its advancement to the younger generation.

Treace Medical Concepts Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Social, Marketing, Patient satisfaction, ACFAS, Bank statement, Tax, Deformity, G&A, GAAP, Research, Pain, Net, EBITDA, Patent, Patient, Investment, American College of Foot and Ankle Surgeons, Bunion, Webcast, Depreciation, Growth, R, American College, Adjustment, S&M, Recurrence, Conference, D, Pharmaceutical industry, Video game, Cryptocurrency, Treace Medical Concepts, Foot

PONTE VEDRA, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • PONTE VEDRA, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2023.
  • Revenue of $42.2 million in the first quarter of 2023, a 45% increase over the same period last year.
  • “First quarter revenue grew 45% with steady execution of our growth strategies and gains across our key operating metrics,” said John T. Treace, CEO, Founder and Board Member of Treace.
  • Gross margin totaled 80.9% in the first quarter of 2023, compared to 82.3% in the first quarter of 2022.